Methods and compositions for treating mesothelioma and small lung cancer that express midkine
US-11026950-B2 · Jun 8, 2021 · US
Methods and compositions for treating mesothelioma and small lung cancer that express midkine
US11672806B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11672806-B2 |
| Application number | US-202117308179-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 5, 2021 |
| Priority date | Jul 28, 2016 |
| Publication date | Jun 13, 2023 |
| Grant date | Jun 13, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating malignant mesothelioma comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier. 2. The method of claim 1 , further comprising administering to said individual a therapeutically effective amount of a BCL-2 inhibitor, wherein said administration of BCL-2 inhibitor is administered serially with the compound of claim 1 , in combination with the compound of claim 1 , simultaneously with the compound of claim 1 , or combinations thereof. 3. The method of claim 2 , wherein said BCL-2 inhibitor is selected from ABT-737, ABT-199, GDC-0199, GX15-070 (Obatoclax), and combinations thereof. 4. The method of claim 1 , further comprising administering to said individual a therapeutically effective amount of 5. The method of claim 1 , wherein ABT-263 is administered in combination with the compound of claim 1 . 6. The method of claim 1 , wherein ABT-263 is administered serially with the compound of claim 1 . 7. The method of claim 1 , wherein ABT-263 is administered simultaneously with the compound of claim 1 . 8. The method of claim 1 , wherein said individual is a mammal. 9. The method of claim 1 , wherein said individual is human.
Assignees
Inventors
Classifications
condensed with heterocyclic ring systems · CPC title
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Antineoplastic agents · CPC title
containing further heterocyclic ring systems · CPC title
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11672806B2 cover?
- Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
- Who is the assignee on this patent?
- Childrens Hospital Med Ct, Cincinnati Childrens Hospital Medical Center
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).